Prothena nets more cash from No­vo Nordisk; Khon­dri­on fails to hit end­point

A year af­ter No­vo Nordisk paid $100 mil­lion up­front to grab Prothena’s an­ti­body and wider pro­gram in AT­TR amy­loi­do­sis, the deal has hit a mile­stone, earn­ing more cash for the biotech.

Prothena an­nounced on Tues­day that it has earned a $40 mil­lion mile­stone pay­ment from the Dan­ish phar­ma. The pay­ment is re­lat­ed to its can­di­date NNC6019, for­mer­ly known as PRX004, a Prothena spokesper­son told End­points News in an email. The com­pa­ny hit the clin­i­cal mile­stone due to the “ini­ti­a­tion of the phase II study,” the spokesper­son said. The can­di­date is meant to treat pa­tients with AT­TR car­diomy­opa­thy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.